Neuroonkologie
Molekulare Diagnostik und Therapie II

Programm

• 11:15 – 11:55 40 Min. 0 Min.

  • Vortrag

  Molekulare Diagnostik

  • Till Acker (Gießen)
• 11:55 – 12:05 7 Min. 3 Min.

  • Abstractvortrag

  Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy – the MecMeth/NOA-24 trial study protocol

  • Matthias Schneider (Bonn)
• 12:05 – 12:15 7 Min. 3 Min.

  • Abstractvortrag

  Resection of recurrent intracranial tumors for molecular diagnostics in the age of precision oncology: A risk-benefit analysis

  • Obada T. Alhalabi (Heidelberg)
• 12:15 – 12:25 7 Min. 3 Min.

  • Abstractvortrag

  Dual CAR-T cell approach in ex vivo glioblastoma models: A new approach to overcome antigen escape mechanisms

  • Marah Alsalkini (Würzburg)
• 12:25 – 12:35 7 Min. 3 Min.

  • Abstractvortrag

  CMV induced MGMT upregulation leads to resistance to alkylating chemotherapy and shortened overall survival in glioblastoma – A prospective, single center observational trial

  • Harald Krenzlin (Mainz)
  • Naureen Keric (Mainz)
• 12:35 – 12:45 7 Min. 3 Min.

  • Abstractvortrag

  Preoperative risk stratification of increased MIB-1 labeling index in pituitary adenoma: A newly proposed prognostic scoring system

  • Ivan Maiseyeu (Bonn)